Tapering Clonazepam in Patients With Panic Disorder After at Least 3 Years of Treatment
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
High-potency benzodiazepines, such as clonazepam, are frequently used in the treatment of panic disorder (PD) because of their rapid onset of action and good tolerability. However, there is concern about their potential to cause withdrawal symptoms. We aimed to develop a protocol for safely tapering off clonazepam in patients with PD who had been receiving treatment for at least 3 years. A specific scale for judging withdrawal was also developed, the Composite Benzodiazepine Discontinuation Symptom Scale. We selected 73 patients with PD who had been asymptomatic for at least 1 year and who wished to discontinue the medication. The trial consisted of a 4-month period of tapering and an 8-month follow-up period. The dosage of clonazepam was decreased by 0.5 mg per 2-week period until 1 mg per day was reached, followed by a decrease of 0.25 mg per week. The mean dosage at the start of tapering was 2.7 +/- 1.2 mg/d. In total, 51 (68.9%) of the patients were free of the medication after the 4 months of tapering according to the protocol, and 19 (26.0%) of the patients needed another 3 months to be free of medication. Clonazepam discontinuation symptoms were mostly mild and included mainly: anxiety, shaking/trembling/tremor, nausea/vomiting, insomnia/nightmares, excessive sweating, tachycardia/palpitations, headache, weakness, and muscle aches. The improvement in PD and general well-being was maintained during both the taper and follow-up phases. Clonazepam can be successfully discontinued without any major withdrawal symptoms if the dose is reduced gradually. We recommend reducing the dosage of clonazepam after intermediate-term use by 0.25 mg/wk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Chiu, W. T., Jin, R., Ruscio, A. M., Shear, K., & Walters, E. E. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.4.415 · Cited by 795 · cited 1×
“5% and 5%.(1) High-potency benzodiazepines, such as clonazepam, usually lead to immediate relief of anxiety and panic attacks (PAs).”
BackgroundLong-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
The benzodiazepine withdrawal symptom questionnaire
Tyrer, P., Murphy, S., & Riley, P. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90009-w · Cited by 188
Protracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170
Mirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders
Croom, K. F., Perry, C. M., & Plosker, G. L. (2009) · CNS Drugs · doi:10.2165/00023210-200923050-00006 · Cited by 158
A Clinical Scale to Assess Benzodiazepine Withdrawal
BUSTO, U. E., SYKORA, K., & SELLERS, E. M. (1989) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198912000-00005 · Cited by 125
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“The efficacy of clonazepam was maintained over a three-year course of treatment [290], and patients who had been asymptomatic for at least one year were able to successfully discontinue the medication, using a slow tapering strategy over four to seven months, and improvement in panic disorder was maintained [296].”
BackgroundBandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086295 · Cited by 158
Self-citationDeprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review
Pollmann, A. S., Murphy, A. L., Bergman, J. C., & Gardner, D. M. (2015) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-015-0019-8 · Cited by 114
“articles or guidelines were included (Additional file 3) [8, 43–180].”
BackgroundRisk versus risk: a review of benzodiazepine reduction in older adults
Paquin, A. M., Zimmerman, K., & Rudolph, J. L. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.925444 · Cited by 82
“Although data cannot be combined given various methods of measurement across studies, frequently cited withdrawal symptoms occurring in > 30% of study subjects included: insomnia, anxiety, irritability/agitation/restlessness, sweating, fatigue/lethargy, tremor and gastrointestinal symptoms such as nausea, vomiting, di…”
BackgroundMethodRisks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines
Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1429403 · Cited by 62
“The main reported symptoms during clonazepam discontinuation were anxiety, irritability, nausea, vomiting, insomnia, nightmares, excessive sudoresis, tachycardia, headache, weakness, shaking, tremor, muscle aches, stiffness, hyperventilation, panic attacks, memory or concentration difficulties, muscle fasciculation, a…”
BackgroundMethod
Metadata
- Authors
- Nardi, A. E., Freire, R. C., Valença, A. M., Amrein, R., de Cerqueira, A. C. R., Lopes, F. L., Nascimento, I., Mezzasalma, M. A., Veras, A. B., Sardinha, A., de Carvalho, M. R., da Costa, R. T., Levitan, M. N., de-Melo-Neto, V. L., Soares-Filho, G. L., & Versiani, M.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2010-06
- Volume
- 30
- Issue
- 3
- Pages
- 290-293
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2033891865
- Cited by
- 41
- References
- 6
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tapering Clonazepam in Patients With Panic Disorder After at Least 3 Years of Treatment. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181dcb2f3
- The paper
- Nardi, A. E., Freire, R. C., Valença, A. M., Amrein, R., de Cerqueira, A. C. R., Lopes, F. L., Nascimento, I., Mezzasalma, M. A., Veras, A. B., Sardinha, A., de Carvalho, M. R., da Costa, R. T., Levitan, M. N., de-Melo-Neto, V. L., Soares-Filho, G. L., & Versiani, M. (2010). Tapering Clonazepam in Patients With Panic Disorder After at Least 3 Years of Treatment. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181dcb2f3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.